Medication Abortion Restrictions & Protections
States continue to diverge sharply on medication abortion, with Washington (SB 5917) easing the distribution of its mifepristone stockpiles, while Wyoming (HB 126) passed a six-week ban (currently judicially blocked) and Mississippi (HB 1613) enacted a strict felony ban on medication abortion. Meanwhile, Ohio (HB 324) targets telemedicine by imposing strict in-person requirements on any drug listed under FDA REMS protocols.
- Washington (SB 5917): Signed into law in March 2026, this bill removes restrictive conditions that made it difficult to distribute the state's stockpiled mifepristone and misoprostol, allowing the medication to be donated to healthcare providers or sold below the original purchase price. This action removes the prior requirement that the Department of Corrections sell abortion medication at cost plus a $5 fee per dose, and directs the Department of Health to assist in identifying appropriate recipients, ensuring the stockpile remains accessible for providers and for patients, including through telehealth prescribing.
- Wyoming (HB 126): Signed into law in March 2026, this bill bans approximately six weeks into pregnancy, with no exceptions for rape or incest. Felonies carry up to five years in prison, a $10,000 fine, or both. A Wyoming court has since blocked the law for violating the state constitution's reproductive healthcare autonomy protections. Telehealth for abortion care is safe and effective well beyond six weeks of pregnancy.
- Mississippi (HB 1613): Signed into law in April 2025, this law makes it a felony to manufacture, distribute, dispense, or prescribe abortion medication, carrying penalties of up to 10 years in prison and civil liability. Taking effect July 1, 2026, this is an attempt to threaten providers prescribing abortion medication into the state.
- Note: this is another attempt by MI to block all forms of abortion care in state, notably, according to the latest WeCount data telehealth abortion in Mississippi continues to steadily rise.
- Ohio (HB 324): Moving through the legislature, this bill targets Mifepristone by focusing on drugs with Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategies (REMS) requirements. Under the latest amendments, prescribing a REMS-listed drug would require an in-person exam and a scheduled follow-up appointment, effectively ending direct-to-patient telehealth medication abortion (TMAB) in Ohio and restricting telehealth access to all medications with REMS requirements, even where the FDA does not mandate an in-person visitation for prescription.
Shield Laws & Controlled Substances Reclassification
Shield laws and drug reclassifications serve as critical legal frontiers to protect healthcare providers. New Jersey (S2260) passed a robust bill shielding local providers and patients from out-of-state investigations, though it excludes telehealth protection across state lines. In response to hostile states classifying reproductive drugs as narcotics, Illinois (SB 4834) passed a committee bill to preemptively prevent the addition of mifepristone, misoprostol, or hormone therapies to the state's controlled substances database.
- New Jersey (S2260): Passed by the Senate in May, this bill shields transgender patients, reproductive healthcare patients, and their providers from out-of-state legal threats and investigations. It criminalizes interference with reproductive and gender-affirming services, carrying up to ten years in prison and a $150,000 fine if injury occurs. While robust for local care, the bill notably does not include shield protections for patients across state lines treated via telehealth.
- Illinois (SB 4834): Passed a Senate committee in a 9-4 vote in April. The bill removes testosterone from the state's controlled substances misuse database and prohibits adding estrogen, mifepristone, misoprostol, or hormone suppressants to the program. The Illinois Department of Human Services would be required to purge existing testosterone prescription records from the state database, serving as a preemptive defense against moves (like Louisiana's in 2024) to classify abortion and hormone therapies as controlled substances to restrict access. This is significant for telehealth access since many state-controlled substance regulations mandate an in-person requirement for prescribing.
- Note: At a federal level, the DEA, working with HHS, issued a Fourth Temporary Extension of the COVID-19-era telemedicine flexibilities for prescribing controlled substances, extending the current telemedicine flexibilities through December 31, 2026. If these flexibilities expire, patient care for scheduled drugs will be disrupted and will once again require a medically unnecessary in person visit.
Telehealth Payment Parity & Reimbursement
Legislative efforts on payment parity seek to stabilize telehealth infrastructure, though loopholes remain a threat. Massachusetts (H5017) filed a comprehensive bill to expand and make permanent full telehealth parity, while New Jersey (AB 4357) introduced a parity bill that includes restrictive carve-outs, such as excluding audio-only physical visits and locking out telehealth-only clinics.
- Massachusetts (H5017): Originally filed in February 2026, the bill would extend full telehealth-to-in-person coverage parity (currently limited to behavioral health), bar insurers from imposing prior authorization on medically necessary telehealth visits that wouldn't apply in person, and require coverage of e-consults and remote patient monitoring. It would also mandate interpreter services and digital health education for patients with limited English proficiency or low digital literacy, fund digital health navigator pilot programs for underserved communities, and create a task force to study interstate telehealth and licensure models. This bill does not include payment parity.
- New Jersey (AB 4357): Introduced in February 2026, this bill permanently extends payment parity requirements (currently set to sunset July 1, 2026) and removes caps on telehealth rates. However, the bill excludes audio-only physical health visits (reimbursable at as little as 50%) and limits full parity to providers who also offer in-person care in New Jersey. This carve-out locks out telehealth-only clinics and harms low-income or rural patients lacking broadband.
Health Data Privacy & AI Transparency
Emerging privacy and technology bills seek to protect sensitive consumer data and regulate digital tools. Massachusetts (H5472) introduced strict protections banning the sale of reproductive healthcare and geolocation data, protecting traveling patients from out-of-state surveillance. New York (S9269/A10357) revised its Health Information Privacy Act to regulate health apps, while Rhode Island (S2570) held a bill requiring clinical disclosures when AI documentation tools are utilized.
- Massachusetts (H5472): Published on June 4, 2026, this bill establishes comprehensive consumer data privacy protections, including a ban on selling or sharing "sensitive data" (explicitly including reproductive and sexual health data) and precise geolocation data without affirmative consent. The protections extend to both residents and visitors, protecting patients traveling to Massachusetts for reproductive or gender-affirming care from surveillance and out-of-state legal exposure while the House and Senate reconcile the bill in conference committee.
- New York S9269 / A10357: A revised version of the New York Health Information Privacy Act has been introduced in the 2026 legislative session following Governor Hochul’s veto of the prior bill in late 2025. The bill regulates the collection, use, and disclosure of consumer health data by non-HIPAA-covered entities (such as health apps and non-traditional wellness platforms), heavily impacting digital reproductive health tracking.
- Notably, the bill has drawn pushback from business and tech groups, including ATA, which argues it would burden care workflows, is overreaching in scope and may harm out-of-state care for telehealth providers.
- The NYCLU strongly supports the bill, arguing it closes a critical gap left by HIPAA and would make it harder for hostile out-of-state actors to use digital data trails to prosecute those seeking abortion or gender-affirming care.
- Rhode Island (S2570): This bill would require healthcare providers to notify patients whenever AI tools are used to document patient visits, whether in-person or via telehealth. Under this law, telehealth providers in Rhode Island would face new mandatory disclosure requirements prior to using digital documentation tools. The bill was held for further study on March 3, 2026.
Expanding TMAB Provider Workforce
- New York: S2360 / A1220: Two companion bills were introduced in January that would permanently remove the July 1, 2026, sunset on New York's Nurse Practitioner Modernization Act. The underlying 2022 law allows NPs with 3,600+ hours of clinical experience to practice without a written physician collaborative agreement; if the legislature does nothing, that authority disappears overnight, forcing experienced NPs to scramble for physicians to work with. For telehealth abortion providers, the impact is direct: NPs who have been prescribing medication abortion independently via telehealth would lose that authority, disrupting access to the care they have relied upon and increasing costs.
- California (16 CCR §1444.5): A proposed regulatory amendment from the California Board of Registered Nursing addresses a gap created by recent laws granting certain APRNs the authority to practice without physician supervision. Because existing probation supervision requirements were written for nurses already working under physician oversight, independently practicing APRNs placed on probation would otherwise be forced to cease practicing entirely. The rulemaking is still in progress.
